Artelo Biosciences, Inc.
corporate_fare Company Profile
Artelo Biosciences, Inc. (NASDAQ:ARTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 52 items for ARTL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ARTL spans 10-Q, 8-K, DEFA14A, PRER14A.
Recent high-impact activity:
- Artelo 10-Q: $4.4M Cash, Going Concern Doubt, $8.8M Nine-Month Cash Burn
- Artelo Flags Nasdaq $5M MVLS Delisting Risk, Weighs More Dilutive Financing
- Artelo Files Patent for ART27.13 Obesity Combo; Stock Surges 194%
- Artelo's ART27.13 Matches Semaglutide Weight Loss, Doubles It in Combo
- Artelo Biosciences Executes 1-for-9 Reverse Split to Regain Nasdaq Compliance
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 27,721 shares in ARTL as of the October 30, 2026 settlement, a 20.2% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 48.3% of ARTL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for ARTL, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
New At-The-Market Offering Launched · Massive Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →